Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPH - Cytoclonal Pharmaceutics -- Ignore unavailable to you. Want to Upgrade?

To: Axxel who wrote (170)	6/16/1998 8:54:00 PM
From: blackmerlin	Read Replies (2) \| Respond to of 428

To all who think taxol will gush into the market soon from CYPH: Those of us who known medicinal chemistry and natural product isolation know that Bristol-Myers Squibb doesn't give a darn about fungal paclitaxel. Yields are too low for fungal paclitaxel to enter the market any time soon. What BMY is after, are the genes involved in the production of paclitaxel. These could then be introduced into any of their workhouse production strains. However the pathways for paclitaxel production is extremely complex and involves mutiple enzyme systems. Only a small amount of knowledge and a few possible genes have been elucidated in the natural pathways involving paclitaxel production. So this is just a start, for BMY to get its foot in the door with CYPH and gain access to these genes (the few possible genes that CYPH now has, although at least this is a beginning). After many, many years, and if CYPH can reach it's milestones, you might see some CYPH-related paclitaxel and some rewards go to CYPH (also if luck smiles on Cytoclonal). This is also alot of competition in this area. Best of luck if you are in it for the long-haul. Regards.